Exchange: NASDAQ·Updated 07:30 PM EDT
News
all
press releases
Faster Answers, Better Decisions: ADLM 2026 Highlights
Faster Answers, Better Decisions: ADLM 2026 Highlights Faster Answers, Better Decisions: ADLM 2026 Highlights PR Newswire SAN DIEGO, Aug. 27, 2026 SAN DIEGO, Aug. 27, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL), a leading global provider of diagnostic solutions, has released episode...
PR Newswire
More News
Here's What Is Shaping Abbott's Diagnostics Growth
ABT's Diagnostics growth is being reshaped as weaker respiratory testing offsets healthy routine demand and 13% cancer diagnostics growth.
Zacks
QDEL's 2026 Outlook Cut Deepens China and Respiratory Risk Concerns
QuidelOrtho's 2026 outlook cut highlights deeper China and respiratory risks, while cash use and rising debt add pressure despite resilient core growth.
Zacks
Is QDEL Worth Buying as China Risks Clash With Resilient Core Growth?
QuidelOrtho's resilient core growth and $50 million cost plan offer support, but China weakness, cash use and heavy debt keep the near-term case cautious.
Zacks
QDEL Rallies 31.7% in Three Months: Can the Stock Keep Climbing Higher?
QuidelOrtho's 31.7% three-month rally meets resilient core growth and cost savings, but China weakness, lower guidance and high debt cloud further gains.
Zacks
QuidelOrtho (QDEL) Q2 2026 Earnings Call Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets
QDEL Q2 Earnings & Revenues Beat Estimates, 2026 Guidance Lowered
QuidelOrtho beats Q2 earnings and revenue estimates, but cuts its 2026 outlook on persistent China weakness and a softer respiratory testing environment.
Zacks
QuidelOrtho Corporation (QDEL) Stock Positioned for Reweighting Towards Peers Amid Deleveraging
QuidelOrtho Corporation (QDEL) Stock Positioned for Reweighting Towards Peers Amid Deleveraging...
Yahoo! Finance: News
Here's How ABT Broadens Diagnostics Growth Base With Oncology Expansion
Abbott broadens Diagnostics growth with Exact Sciences, as Cancer Diagnostics gains and resilient routine testing offset respiratory weakness.
Zacks
QuidelOrtho (QDEL) Surpasses Q2 Earnings and Revenue Estimates
QuidelOrtho (QDEL) delivered earnings and revenue surprises of +425.00% and +2.65%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks

Advertisement|Remove ads.